advertisement
Abstract #5358 Published in IGR 1-2
The comparative ocular hypotensive effect of apraclonidine with timolol maleate in exfoliation versus primary open-angle glaucoma patients
Konstas AGP; Maltezos A; Mantziris DA; Sine CS; Stewart WCEye 1999; 13: 314-318
PURPOSE: To compare the effect of adding apraclonidine 0.5% to timolol maleate 0.5% in patients with exfoliation versus primary open-angle glaucoma. Since exfoliation glaucoma is known to demonstrate higher pressures than primary open-angle glaucoma on timolol maleate therapy alone, the authors wished to determine whether apraclonidine equalized the intraocular pressure (IOP) between these two glaucomas when added to timolol maleate. METHODS: We age-matched 30 consecutive exfoliation and 30 primary open-angle glaucoma patients who had an IOP >22 mmHg on timolol maleate alone. Patients underwent IOP diurnal curve testing on timolol maleate twice daily alone and, 2 months later, following the addition of apraclonidine 0.5% three times daily. Statistical analysis of the IOP at each time point was by an unpaired t test between groups. A paired t test was used to evaluate the reduction in IOP from baseline within groups after the addition of apraclonidine. RESULTS: On timolol maleate alone, exfoliation patients had a higher mean IOP at 06:00 and 10:00 hours, as well as a higher peak, range and standard deviation of the IOP compared with primary open-angle glaucoma patients (p<0.05). Following the addition of apraclonidine, the mean, peak, and range of IOP were statistically similar between groups, and only the standard deviations remained higher in the exfoliation glaucoma group (p<0.001). The mean diurnal IOP after apraclonidine was added, was 20.5 ? 7.0 mmHg in the exfoliation glaucoma group and 20.0 ? 3.4 mmHg in the primary open-angle glaucoma group, which was not significantly different between groups (p=0.73). CONCLUSIONS: This study suggests that apraclonidine 0.5% used adjunctively with timolol maleate 0.5% solution is generally associated with similar IOP control in exfoliation and primary open-angle glaucoma patients.
W.C. Stewart, Pharmaceutical Research Corporation, 1639 Tatum Street, Charleston, SC 29412-2454; USA
Classification:
9.4.4.1 Exfoliation syndrome (Part of: 9 Clinical forms of glaucomas > 9.4 Glaucomas associated with other ocular and systemic disorders > 9.4.4 Glaucomas associated with disorders of the lens)
11.4 Prostaglandins (Part of: 11 Medical treatment)